Prostate cancer in Asian men

Nature Reviews Urology

Volumn 11, Issue 4, 2014, Pages 197-212

  Ito, Kazuto ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ASIAN; CANCER GENETICS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER SCREENING; DIETARY INTAKE; HUMAN; LIFE EXPECTANCY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; SHORT SURVEY;

ASIA; DIET; EARLY DETECTION OF CANCER; HUMANS; INCIDENCE; MALE; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84901198148     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2014.42     Document Type: Short Survey

References (100)

1. Ferlay, J. et al. GLOBOCAN 2008, Cancer incidence and mortality worldwide: IARC Cancer Base No. 10. (International Agency for Research on Cancer, 2010).
2. Howlader, N. et al. (eds). SEER Cancer Statistics Review, 1975-2010 [online], http://seer.cancer.gov/csr/1975-2010/ based on November 2012 SEER data submission, posted to the SEER website (National Cancer Institute, 2013).
3. Nukaga, K., Matsuda, T. & Sobue, T. Prediction of the future mortality of cancer in Japan in White Paper on Cancer and Statistics 2012 [Japanese], (eds Sobue, T., Katanoda, K., Ajiki, W., Tsukuma, H. & Ioka, A.) 84-99 (2012).
4. Eser, S. et al. Cancer incidence rates in Turkey in 2006: a detailed registry based estimation. Asian Pacific J. Cancer Prev. 11, 1731-1739 (2010).
5. Matsuda, T. et al. Cancer incidence and incidence rates in Japan in 2004: based on data from 14 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J. Clin. Oncol. 40, 1192-1200 (2010).
6. Moore, M. A. et al. Cancer epidemiology and control in Peninsular and Island South-East Asia - past, present and future. Asian Pacific J. Cancer Prev. 9, 81-98 (2008).
7. Long, N. et al. Cancer epidemiology and control in North-East Asia - past, present and future. Asian Pacific J. Cancer Prev. 10, 107-148 (2010).
8. Xie, W. C., Chan, M. H., Mak, K. C., Chan, W. T. & He, M. Trends in the incidence of 15 common cancers in Hong Kong, 1983-2008. Asian Pacific J. Cancer Prev. 13, 3911-3916 (2012).
9. Ylmaz, H. H. et al. Cancer trends and incidence and mortality patterns in Turkey. Jpn J. Clin. Oncol. 41, 10-16 (2011).
10. Moore, M. A. et al. Cancer epidemiology and control in North-Western and Central Asia - past, present and future. Asian Pacific J. Cancer Prev. 11 (Suppl.), 17-32 (2010).
11. Moore, M. A. et al. Cancer epidemiology in South Asia - past, present and future. Asian Pacific J. Cancer Prev. 10 (Suppl.), 49-67 (2009).
12. Manoharan, N., Tyagi, B. B. & Raina, V. Cancer incidences in urban Delhi - 2001-2005. Asian Pacific J. Cancer Prev. 10, 799-806 (2009).
13. Swaminathan, R. et al. Trends in cancer incidence in Chennai city (1982-2006) and statewide predictions of future burden in Tamil Nadu (2007-2016). Natl Med. J. India 24, 72-77 (2011).
14. Moore, M. A. et al. Cancer epidemiology in Mainland South-East Asia - past, present and future. Asian Pacific J. Cancer Prev. 9, 67-80 (2008).
15. Salim, E. I. et al. Cancer epidemiology in South: West Asia - past, present and future. Asian Pacific J. Cancer Prev. 10, 33-50 (2009).
16. Song, F. et al. A cancer incidence survey in Tianjin: the third largest city in China - between 1981 and 2000. Cancer Causes Control 19, 443-450 (2008).
17. Teo, M. C. & Soo, K. C. Cancer trends and incidences in Singapore. Jpn J. Clin. Oncol. 43, 219-224 (2013).
18. Miller B. A., Chu, K. C., Hankey, B. F. & Ries, L. A. Cancer incidence and mortality patterns among specific Asian and Pacific Islander populations in the US. Cancer Causes Control 19, 227-256 (2008).
19. Shin, H. R., Masuyer, E., Ferlay, J. & Curado, M. P. Cancer in Asia - incidence rates based on data in Cancer Incidence in Five Continents IX (1998-2002). Asian Pacific J. Cancer Prev. 11 (Suppl.), 11-16 (2010).
20. Ranasinghe, W. K., Sibanda T., de Silva M. V., Ranasinghe, T. I. & Persad, R. Incidence of prostate cancer in Sri Lanka using cancer registry data and comparisons with the incidence in South Asian men in England. BJU Int. 108, E184-E189 (2011).
21. Center, M. M. et al. International variation in prostate cancer incidence and mortality rates. Eur. Urol. 61, 1079-1092 (2012).
22. Mousavi, S. M. Toward prostate cancer early detection in Iran. Asian Pacific J. Cancer Prev. 10, 413-418 (2009).
23. Habib, O. S. et al. Cancer registration in Basrah 2005: preliminary results. Asian Pacific J. Cancer Prev. 8, 187-190 (2007).
24. Salim, E. I. et al. Cancer epidemiology in South-West Asia - past, present and future. Asian Pacific J. Cancer Prev. 10, 33-50 (2009).
25. Ghafoor, M., Schuyten, R. & Bener, A. Epidemiology of prostate cancer in United Arab Emirates. Med. J. Malaysia 58, 712-716 (2003). (Pubitemid 38480485)
26. Cullen, J. et al. The burden of prostate cancer in Asian nations. J. Carcinog. 11, 7 (2012).
27. Sandagdorj, T. et al. Cancer incidence and mortality in Mongolia - national registry data. Asian Pacific J. Cancer Prev. 11, 1509-1514 (2010).
28. Lim, G. H., Chow, K. Y. & Lee, H. P. Singapore cancer trends in the last decade. Singapore Med. J. 53, 3-10 (2012).
29. Curado, M. P. et al. Cancer Incidence in Five Continents: Vol. 9. IARC Scientific Publications No. 160 (International Agency for Research on Cancer, 2007).
30. Jung, K. W. et al. Long-term trends in cancer mortality in Korea (1983-2007): a joinpoint regression analysis. Asian Pacific J. Cancer Prev. 11, 1451-1457 (2010).
31. Jemal, A., Siegel, R., Xu, J. & Ward, E. Cancer statistics, 2010. CA Cancer J. Clin. 60, 277-300 (2010).
32. Ito, K. et al. Impact of exposure rate of PSA-screening on clinical stage of prostate cancer in Japan. J. Urol. 175 (Suppl.), 477-478 (2006).
33. Sirovich, B. E., Schwartz, L. M. & Woloshin, S. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? JAMA 289, 1414-1420 (2003). (Pubitemid 37430309)
34. Jung, K. W. et al. Cancer statistics in Korea: incidence, mortality and survival in 2006-2007. J. Korean Med. Sci. 25, 1113-1121 (2010).
35. Chia, S. E. et al. Incidence, mortality and five-year relative survival ratio of prostate cancer among Chinese residents in Singapore from 1968 to 2002 by metastatic staging. Ann. Acad. Med. Singapore 39, 466-471 (2010).
36. Matsuda, T. et al. Population-based survival of cancer patients diagnosed between 1993 and 1999 in Japan: a chronological and international comparative study. Jpn J. Clin. Oncol. 41, 40-51 (2011).
37. Fukagai, T., Namiki, T. S., Carlile, R. G., Yoshida, H. & Namiki, M. Comparison of the clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men. BJU Int. 97, 1190-1193 (2006). (Pubitemid 43907319)
38. Fujimoto, H. et al. Oncological outcomes of the prostate cancer patients registered in 2004: report from the Cancer Registration Committee of the JUA. Int. J. Urol. 18, 876-881 (2011).
39. Crawford, E. D. Epidemiology of prostate cancer. Urology 62 (Suppl. 1), 3-12 (2003). (Pubitemid 38050194)
40. Xia, S. J., Cui, D. & Jiang, Q. An overview of prostate diseases and their characteristics specific to Asian men. Asian J. Androl. 14, 458-464 (2012).
41. Hsing, A. W., Tsao, L. & Devesa, S. S. International trends and patterns of prostate cancer incidence and mortality. Int. J. Cancer 85, 60-67 (2000).
42. Zhang, L. et al. Prostate cancer: an emerging threat to the health of aging men in Asia. Asian J. Androl. 13, 574-578 (2011).
43. McCracken, M. et al. Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J. Clin. 57, 190-205 (2007). (Pubitemid 47312080)
44. Qiu, D., Katanoda, K., Marugame, T. & Sobue, T. A joinpoint regression analysis of long-term trends in cancer mortality in Japan (1958-2004). Int. J. Cancer 124, 443-448 (2009).
45. Zhang, J., Dhakal, I. B., Zhao, Z. & Li, L. Trends in mortality from cancers of the breast, colon, prostate, esophagus, and stomach in East Asia: role of nutrition transition. Eur. J. Cancer Prev. 21, 480-489 (2012).
46. Yatani, R. et al. Geographic pathology of latent prostatic carcinoma. Int. J. Cancer 29, 611-616 (1982). (Pubitemid 12089197)
47. Karube, K. Study of latent carcinoma of the prostate in the Japanese based on necropsy material. Tohoku J. Exp. Med. 74, 265-285 (1961).
48. Akazaki, K. & Stemmerman, G. N. Comparative study of latent carcinoma of the prostate among Japanese in Japan and Hawaii. J. Natl Cancer Inst. 50, 1137-1144 (1973).
49. Wada, T. Histopathological analysis of latent prostatic carcinoma in Japan [Japanese]. Jpn J. Urol. 78, 2065-2070 (1987).
50. Parkin, D. M. et al. Cancer incidence in five continents Vol. I to VIII: international comparison of age-standardized incidence rates for prostate cancer in selected registries, males, 1993-1996 (IARC CancerBase No. 7, 2005).
51. Cussenot, O. & Valeri, A. Heterogeneity in genetic susceptibility to prostate cancer. Eur. J. Int. Med. 12, 11-16 (2001). (Pubitemid 32112076)
52. Carter, B. S. et al. Hereditary prostate cancer: epidemiologic and clinical features. J. Urol. 150, 797-802 (1993).
53. World Cancer Research Fund and American Institute for Cancer Research. Food, Nutrition, Physical activity, and the Prevention of Cancer: a Global Perspective 305-309 (American Institute for Cancer Research, 2007).
54. Otake, N. et al. Clinical characteristics of hereditary and familial prostate cancer in Japan [Japanese]. J. Familial Tumors 11, 5-10 (2011).
55. Suzuki, H. et al. CAG polymorphic repeat lengths in androgen receptor gene among Japanese prostate cancer patients: potential predictor of prognosis after endocrine therapy. Prostate 51, 219-224 (2001). (Pubitemid 34492643)
56. Hsing, A. W. et al. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study. Epidemiol. Biomarkers Prev. 10, 1077-1082 (2001).
57. Tsuchiya, N. et al. Impact of IGF: I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer. J. Clin. Oncol. 24, 1982-1989 (2006).
58. Suzuki, K. et al. A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese. J. Biomed. Sci. 10, 430-435 (2003).
59. Matsui, H. et al. Genomewide linkage analysis of familial prostate cancer in the Japanese population. J. Hum. Genet. 49, 9-15 (2004).
60. Fukuma, Y. et al. Role of squalene synthase in prostate cancer risk and the biological aggressiveness of human prostate cancer. Prostate Cancer Prostatic Dis. 15, 339-345 (2012).
61. Carpten, J. et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat. Genet. 30, 181-184 (2002).
62. Rökman, A. et al. Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am. J. Hum. Genet. 70, 1299-1304 (2002). (Pubitemid 34450579)
63. Nakazato, H. et al. Role of genetic polymorphisms of the RNASEL gene on familial prostate cancer risk in a Japanese population. Br. J. Cancer 89, 691-696 (2003). (Pubitemid 37076175)
64. Hamano, T. et al. Association of SNP rs1447295 and microsatellite marker DG8S737 with familial prostate cancer and high grade disease. J. Urol. 184, 738-742 (2010).
65. Zheng, J. et al. Green tea and black tea consumption and prostate cancer risk: an exploratory meta-analysis of observational studies. Nutr. Cancer 63, 663-672 (2011).
66. Yan, L. & Spitznagel, E. L. Soy consumption and prostate cancer risk in men: a revisit of a meta-analysis. Am. J. Clin. Nutr. 89, 1155-1163 (2009).
67. Kurahashi, N., Iwasaki, M., Inoue, M., Sasazuki, S. & Tsugane, S. Plasma isoflavones and subsequent risk of prostate cancer in a nested case-control study: the Japan Public Health Center. J. Clin. Oncol. 26, 5923-5929 (2008).
68. Ito, K. et al. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening. Cancer 103, 242-250 (2005). (Pubitemid 40129282)
69. McGreevy, K., Rodgers, K., Lipsitz, S., Bissada, N. & Hoel, D. Impact of race and baseline PSA on longitudinal PSA. Int. J. Cancer 118, 1773-1176 (2006).
70. Candas, B. et al. Relationship among initial serum prostate specific antigen, prostate specific antigen progression and prostate cancer detection at repeat screening visits. J. Urol. 175, 510-516 (2006).
71. Ohi, M. et al. Changes in baseline PSA levels in Japanese men from 1988 to 2003. Urology 72, 95-98 (2008).
72. Yuan, X. D. et al. Distribution of serum prostate-specific antigen in Chinese healthy men: a population-based study. Chin. Med. J. (Engl.) 124, 1189-1192 (2011).
73. He, D. et al. Ethnic differences in distribution of serum prostate-specific antigen: a study in a healthy Chinese male population. Urology 63, 722-726 (2004). (Pubitemid 38479417)
74. Chia, S. E. et al. Prostate-specific antigen levels among Chinese, Malays and Indians in Singapore from a community-based study. Asian Pacific J. Cancer Prev. 8, 375-378 (2007).
75. Khezri, A. A. et al. Age-specific reference levels of serum prostate-specific antigen, prostate volume and prostate specific antigen density in healthy Iranian men. Iran. J. Immunol. 6, 40-48 (2009).
76. Oesterling, J. E. et al. Serum PSA in a community-based population of healthy Japanese men: lower values than for similarly aged White men. Br. J. Urol. 75, 347-353 (1995).
77. Lee, S. E. et al. Ethnic differences in the age-related distribution of serum prostate-specific antigen values: a study in a healthy Korean male population. Urology 56, 1007-1010 (2000).
78. Ku, J. H. et al. Distribution of serum prostate-specific antigen in healthy Korean men: influence of ethnicity. Urology 60, 475-479 (2002). (Pubitemid 35292177)
79. Png, J. C., Akhtar, K. J. & Tung, K. H. Role of PSA testing in multiphasic health screening. Singapore Med. J. 39, 193-195 (1998).
80. Battikhi, M. N. Age-specific reference ranges for prostate-specific antigen (PSA) in Jordanian patients. Prostate Cancer Prostatic Dis. 6, 256-260 (2003). (Pubitemid 37185157)
81. Rabah, D. M. & Arafa, M. A. Prostate cancer screening in a Saudi population: an explanatory trial study. Prostate Cancer Prostatic Dis. 13, 191-194 (2010).
82. Kehinde, E. O. et al. Age-specific reference levels of serum prostate-specific antigen and prostate volume in healthy Arab men. BJU Int. 96, 308-312 (2005). (Pubitemid 41097671)
83. Nomura, M. et al. Development and external validation of a nomogram for predicting cancer probability at initial prostate biopsy using the life expectancy-adjusted and prostate volume-adjusted biopsy scheme. Prostate Cancer Prostatic Dis. 15, 202-209 (2012).
84. [No authors listed] Nation-wide surveys on screening for prostate cancer. Reports between 2001 and 2005 [Japanese] (Japanese Foundation for Prostate Research, 2011).
85. Pu, Y. S. Prostate cancer in Taiwan: epidemiology and risk factors. Int. J. Androl. 23 (Suppl. 2), 34-36 (2000).
86. Peyromaure, E. M. et al. A comparative study of prostate cancer detection and management in China and in France. Can. J. Urol. 16, 4472-4477 (2009).
87. Dai, B., Ye, D. W., Kong, Y. Y., Shen, Y. J. & Wang, B. H. Individualized prostate biopsy strategy for Chinese patients with different prostate-specific antigen levels. Asian J. Androl. 10, 325-331 (2008). (Pubitemid 351337998)
88. Peyromaure, M. et al. Management of prostate cancer in China: a multicenter report of 6 institutions. J. Urol. 174, 1794-1797 (2005).
89. Zhang, H. F. et al. Mass screening of 12,027 elderly men for prostate carcinoma by measuring serum prostate specific antigen. Chin. Med. J. (Engl.) 117, 67-70 (2004).
90. Cancer Registration Committee of the Japanese Urological Association. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int. J. Urol. 12, 46-61 (2005).
91. Okihara, K. et al. Clinical characteristics of prostate cancer in Japanese men in the eras before and after serum prostate-specific antigen testing. Int. J. Urol. 12, 662-667 (2005). (Pubitemid 41725492)
92. Kubota, Y., Ito, K., Imai, K. & Yamanaka, H. Effectiveness of mass screening for the prognosis of prostate cancer patients in Japanese communities. Prostate 50, 262-269 (2002). (Pubitemid 34184666)
93. Takechi, H. et al. Correlation between exposure rates of screening for prostate cancer and clinical features of patients diagnosed with prostate cancer in Gunma Prefecture, Japan [Japanese]. Jpn J. Urol. Surg. 18, 997-999 (2005).
94. Raymundo, E. M., Rice, K. R., Chen, Y., Zhao, J. & Brassell, S. A. Prostate cancer in Asian Americans: incidence, management and outcomes in an equal access healthcare system. BJU Int. 107, 1216-1222 (2011).
95. Committee for Establishment of the Guidelines on Screening for Prostate Cancer; Japanese Urological Association. Updated Japanese Urological Association Guidelines on prostate-specific antigen-based screening for prostate cancer in 2010. Int. J. Urol. 17, 830-838 (2010).
96. Schröder, F. H. et al. Prostate-cancer mortality at 11 years of follow-up. N. Engl. J. Med. 366, 981-990 (2012).
97. Hugosson, J. et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 11, 725-732 (2010).
98. Ito, K. et al. Japanese Urological Association guidelines on prostate-specific antigen-based screening for prostate cancer and the ongoing cluster cohort study in Japan. Int. J. Urol. 15, 763-768 (2008).
99. Ahmad, O. et al. Age standardization of rates: a new WHO standard. GPE Discussion Paper Series: No. 31 (World Health Organization, 2000).
100. World Health Organization (WHO). Global Health Observatory Data Repository; Life expectancy: Life expectancy by country [online], http://apps.who.int/gho/data/view.main.680lang=en (2013).